Terminated PHASE2 INTERVENTIONAL 1-arm NCT00272181

Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease

Sponsor: Sesen Bio, Inc.

Conditions Carcinoma, Squamous Cell Head and Neck Cancer Head and Neck Neoplasms Mouth Neoplasms Neoplasms, Squamous Cell Squamous Cell Carcinoma of the Head and Neck

Interventions Proxinium

Updated 8 times since 2017 Last updated: Dec 22, 2015 Started: Jan 31, 2006 Primary completion: Oct 31, 2007 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow accrual in North America

Other terminated trials from Sesen Bio, Inc.

More terminations from Sesen Bio, Inc.

Other Carcinoma, Squamous Cell trials with similar outcome

Browse all Carcinoma, Squamous Cell trials

This PHASE2 trial investigates Carcinoma, Squamous Cell and Head and Neck Cancer and is currently terminated or withdrawn. Sesen Bio, Inc. leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2022 [monthly]

Terminated PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sesen Bio, Inc.

Data source: Sesen Bio, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birmingham, United States , Boston, United States , Charleston, United States , Dallas, United States , Denver, United States , Evanston, United States , Harvey, United States , Kansas City, United States , Lebanon, United States , Little Rock, United States and 9 more locations